Review of the effects of 17α‐estradiol in humans: a less feminizing estrogen with neuroprotective potential
Authors:
- 9 February 2009
- journal article
- review article
- Published by Wiley in Drug Development Research
- Vol. 70 (1) , 1-21
Abstract
17α‐Estradiol is a less feminizing isomer of the potent hormonal estrogen, 17β‐estradiol. 17α‐Estradiol is an orally active small molecule with conflicting reports of efficacy in preclinical models of degenerative diseases. A number of studies suggest neuroprotective potential in human neurodegenerative disorders, including Alzheimer's disease (AD) and Parkinson's disease. Several studies have established an antioxidant effect of 17α‐estradiol in humans. The sodium salt of 17α‐estradiol 3‐sulfate is a minor component (2.5–9.5%) of several widely marketed estrogen hormone replacement products, such as Premarin®, that are approved by the U.S. Food and Drug Administration and have been prescribed and studied in women and men for more than 65 years. Most of the more than 100 published reports on the neurological effects of feminizing estrogens found positive responses in at least one measure relating to cognition or prevention and treatment of AD, notwithstanding the negative results in the Women's Health Initiative studies. Whether these limited, and often not statistically significant, findings are clinically meaningful remains unknown. In many in vitro and in vivo preclinical neuroprotection and related studies, 17α‐estradiol and 17β‐estradiol are active at similar concentrations and doses. However, 17α‐estradiol is less pleiotropic than 17β‐estradiol, and thus its potential toxicity might be lower. Given decades of mixed reports regarding the potential efficacy and safety of strongly feminizing hormones in neurodegenerative diseases, the weakly feminizing 17α‐estradiol might be a suitable candidate for clinical testing of the neuroprotective potential of this chemical class because it avoids, or significantly reduces, the adverse effects of potent hormonal compounds. Drug Dev Res 70:1–21, 2009.Keywords
This publication has 93 references indexed in Scilit:
- Nuclear and Extranuclear Estrogen Binding Sites in the Rat Forebrain and Autonomic Medullary AreasEndocrinology, 2008
- Estrogen Therapy and Coronary-Artery CalcificationNew England Journal of Medicine, 2007
- HRT and the Young at HeartNew England Journal of Medicine, 2007
- Timing of estrogen therapy after ovariectomy dictates the efficacy of its neuroprotective and antiinflammatory actionsProceedings of the National Academy of Sciences, 2007
- 17‐β‐Estradiol‐mediated activation of extracellular‐signal regulated kinase, phosphatidylinositol 3‐kinase/protein kinase B‐Akt and N‐methyl‐d‐aspartate receptor phosphorylation in cortical synaptoneurosomesJournal of Neurochemistry, 2007
- Impact of the selective estrogen receptor modulator, tamoxifen, on neuronal outgrowth and survival following toxic insults associated with aging and Alzheimer's diseaseExperimental Neurology, 2004
- Evaluation of Single- and Multiple-Dose Pharmacokinetics of Synthetic Conjugated Estrogens, A (Cenestin®) Tablets: A Slow-Release Estrogen Replacement ProductThe Journal of Clinical Pharmacology, 2002
- Estradiol Exerts Neuroprotective Effects When Administered After Ischemic InsultStroke, 2000
- Identification of oestrogen metabolites in human urine by capillary gas chromatography and mass spectrometryJournal of Mass Spectrometry, 1989
- Enzymic synthesis of steroid sulphates XIV. Properties of human adrenal steroid alcohol sulphotransferaseBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1981